DHTKD1 and cancer: Kawashima et al. developed the modified adenovirus type 5 wherein both E1A and E1B genes were controlled by a single hTERT promoter resulting in improved cancer specificity (OBP-301, Telomelysin, Oncolys BioPharma Inc., Tokyo, Japan) [71].